Livzon Clarifies 2025 Dividend Plan, Confirms RMB14.30 per 10 Shares

Livzon Pharmaceutical Group ( (HK:1513) ) has provided an update.

Livzon Pharmaceutical Group has issued a supplemental clarification to its previously announced 2025 profit distribution plan, correcting an earlier wording that could mislead investors about the size of the planned cash dividend. The company confirmed that the proposed payout is RMB14.30 (tax inclusive) for every 10 shares held on the equity registration date, with no bonus shares and no capitalization of capital reserves, and that the plan remains subject to shareholder approval at the 2025 shareholders’ meeting.

By reaffirming that only this clarification is being made and all other details in its earlier disclosures are unchanged, Livzon aims to ensure shareholders have an accurate understanding of its intended cash return policy for 2025. The move helps avoid confusion over dividend expectations per share, supports transparency in investor communications, and may influence income-focused shareholders’ assessment of the stock’s yield and capital allocation strategy once the plan is approved.

The most recent analyst rating on (HK:1513) stock is a Hold with a HK$29.00 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.

More about Livzon Pharmaceutical Group

Livzon Pharmaceutical Group Inc. is a China-based pharmaceutical company listed in Hong Kong, engaged in the research, development, manufacture, and sale of pharmaceutical products. The group focuses on prescription and over-the-counter medicines, serving domestic and international healthcare markets and targeting both hospital and retail pharmacy channels.

Average Trading Volume: 773,968

Technical Sentiment Signal: Hold

Current Market Cap: HK$30.28B

For a thorough assessment of 1513 stock, go to TipRanks’ Stock Analysis page.